医学
细胞凋亡
癌症
肿瘤坏死因子α
单克隆抗体
癌细胞
癌症研究
受体
程序性细胞死亡
免疫学
抗体
生物
内科学
生物化学
作者
Deepika Singh,Mallika Tewari,Sunita Singh,Gopeshwar Narayan
出处
期刊:Future Oncology
[Future Medicine]
日期:2021-02-01
卷期号:17 (5): 581-596
被引量:18
标识
DOI:10.2217/fon-2020-0727
摘要
TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, can induce apoptosis in cancer cells, sparing normal cells when bound to its associated death receptors (DR4/DR5). This unique mechanism makes TRAIL a potential anticancer therapeutic agent. However, clinical trials of recombinant TRAIL protein and TRAIL receptor agonist monoclonal antibodies have shown disappointing results due to its short half-life, poor pharmacokinetics and the resistance of the cancer cells. This review summarizes TRAIL-induced apoptotic and survival pathways as well as mechanisms leading to apoptotic resistance. Recent development of methods to overcome cancer cell resistance to TRAIL-induced apoptosis, such as protein modification, combination therapy and TRAIL-based gene therapy, appear promising. We also discuss the challenges and opportunities in the development of TRAIL-based therapies for the treatment of human cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI